BRAF and melanoma: Recently, detection of the BRAF V600E mutation by immunohistochemistry (IHC) using the anti-BRAF V600E monoclonal VE1 antibody was found to be possible in melanoma, thyroid carcinoma, and colorectal cancer [11,12,13,14,15].